Sinaiko Urology Announces Launch of HIFU Prostate Treatment Blog

Share Article

Renown urologist, Peter Sinaiko, MD FACS, launches new blog to educate patients, medical professionals and regulators about the efficacy of HIFU therapy for treatment of prostate cancer. The blog is located at

Sonablate Equipment Used for HIFU Therapy

The Sonablate 500 Equipment Used for HIFU Therapy

HIFU therapy consistently results in similar efficacy outcomes as other prostate cancer treatments, but without the risk of incontinence or impotence.

Sinako Urology, led by Peter Sinako, MD FACS, announced that it has launched a website and blog dedicated to the coverage of High Intensity Focused Ultrasound or HIFU for the treatment of prostate cancer located at

This emerging therapy has gained approval for use throughout many countries worldwide, but has yet to gain FDA approval in the United States. Therefore, patients seeking HIFU therapy must travel outside U.S. borders to receive this treatment, which greatly preserves a man’s quality of life compared to other treatment methods such as surgery and radiation.

“Over the course of treating prostate cancer patients for several decades using every available modality, I have come to believe that for many patients, HIFU can be their ultimate treatment option.” said Dr. Sinaiko. “Therefore it is my goal to facilitate the use of HIFU therapy within the US as well as abroad, so that patients can consider this option as a viable form of treatment, which virtually removes the risk of impotence or incontinence.”

Dr. Sinaiko has successfully treated many patients offering the therapy through his association with International HIFU. His new blog is dedicated to educating patients, medical professionals and regulators alike regarding the practice of HIFU in treating prostate where the cancer is limited to the prostate gland without distant spread.

The timing of Dr. Sinaiko’s blog comes on the heals of recent news that the US Preventive Services Task Force (USPSTF) now recommends against routine prostate-specific antigen (P.S.A.) screening. The organization bases the recommendation on the belief that the risks of erectile dysfunction, urinary incontinence, and bowel dysfunction caused by prostatectomy and radiation treatment, can outweigh the benefits of treating the cancer.

According to Dr. Sinaiko, that is an excellent reason why HIFU therapy for the treatment of prostate cancer should gain FDA approval for use within the US and that men should continue P.S.A. screenings. “HIFU therapy consistently results in similar efficacy outcomes as other prostate cancer treatments, but without the risk of incontinence or impotence,” he adds.

Currently the most common form of treatment of prostate cancer in the U.S. is surgical removal of the entire prostate gland, which Dr. Sinaiko believes is unnecessary in a majority of cases where the cancer has been detected by PSA screening. HIFU, on the other hand, is a minimally-invasive procedure that destroys unhealthy tissue through rapid heat elevation focused at a specific location. Unlike more invasive procedures, HIFU preserves the urethral sphincter, nerves and surrounding tissue that can become damaged during surgery and radiation. HIFU therapy typically requires about a 4-hour procedure performed under anesthesia on an outpatient basis. Patients are able to resume almost all of their normal activities after a few days with few exceptions.

Dr. Sinaiko welcomes all questions, suggestions and comments that he can address on his blog located at

For more information, contact Peter Sinaiko, MD FACS , Sinaiko Urology at (215) 757-6300 or by email at: sinaikourology(at)gmail(dot)com . Visit to learn more about the use of HIFU therapy in the treatment of prostate cancer.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Sinaiko, MD FACS
Visit website